Lipella Pharmaceuticals (NASDAQ:LIPO) Issues Quarterly Earnings Results

Lipella Pharmaceuticals (NASDAQ:LIPO) issued its quarterly earnings data on Thursday. The company reported ($1.19) earnings per share (EPS) for the quarter, Zacks reports. Lipella Pharmaceuticals had a negative net margin of 882.82% and a negative return on equity of 192.33%. The company had revenue of $0.17 million for the quarter.

Lipella Pharmaceuticals Price Performance

Shares of NASDAQ LIPO opened at $2.59 on Friday. Lipella Pharmaceuticals has a 1 year low of $2.02 and a 1 year high of $12.00. The stock has a market capitalization of $3.13 million, a P/E ratio of -0.61 and a beta of 0.13. The company’s 50-day moving average is $2.89 and its 200 day moving average is $3.03.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).